Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of IPI-145 (duvelisib) in Refractory Indolent Non-Hodgkin Lymphoma
2013-004008-20Phase 2Completed
- Sponsor
- Verastem Oncology
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and 1 more, sponsored by Verastem Oncology. Primary endpoint: Overall Response Rate. Started Nov 2013; status: completed.
02
Drugs
duvelisib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-004008-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004008-20.